On August 1, 2026, it was reported that BlackRock Inc. had significantly reduced its stake in Axsome Therapeutics, selling 1,176,341 shares on June 30, 2026. This sale represented a 30.06% decrease in BlackRock's holdings of the biopharmaceutical company. The shares were sold at a price of $244.77 each.
Following the sale, BlackRock still holds 2,736,503 shares, which accounts for 5.30% of Axsome's outstanding shares. The disclosure of this large transaction from a major institutional investor could signal a potential shift in sentiment regarding Axsome's near-term prospects, especially given the stock's recent volatility and the sale price being notably higher than the current market price of $217.99.